Clinical studies using the microtubule-targeting agent
2-methoxyestradiol (2ME2;
Panzem) in
cancer patients show that treatment is associated with clinical benefit, including prolonged stable disease, complete and partial responses, and an excellent safety profile. Studies have shown that 2ME2 is metabolized by conjugation at positions 3 and 17 and oxidation at position 17. To define structure-activity relationships for these positions of 2ME2 and to generate metabolically stable analogues with improved anti-
tubulin properties, a series of analogues was generated and three lead analogues were selected,
ENMD-1198, ENMD-1200, and ENMD-1237. These molecules showed improved metabolic stability with >65% remaining after 2-h incubation with hepatocytes. Pharmacokinetic studies showed that
oral administration of the compounds resulted in increased plasma levels compared with 2ME2. All three analogues bind the
colchicine binding site of
tubulin, induce G(2)-M cell cycle arrest and apoptosis, and reduce
hypoxia-inducible factor-1alpha levels.
ENMD-1198 and ENMD-1200 showed improved in vitro antiproliferative activities. Significant reductions in
tumor volumes compared with vehicle-treated mice were observed in an orthotopic
breast carcinoma (MDA-MB-231) xenograft model following daily oral treatment with all compounds (ANOVA, P < 0.05). Significantly improved median survival time was observed with
ENMD-1198 and ENMD-1237 (200 mg/kg/d) in a
Lewis lung carcinoma metastatic model (P < 0.05). In both
tumor models, the high-dose group of
ENMD-1198 showed antitumor activity equivalent to that of
cyclophosphamide.
ENMD-1198 was selected as the lead molecule in this analogue series and is currently in a phase I clinical trial in patients with refractory solid
tumors.